High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 10.5% by NIFTY 50.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Profitability: Very strong Profitability. One year profit margin are 32%.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 8.1% in last 30 days.
Insider Trading: Significant insider selling noticed recently.
Valuation | |
|---|---|
| Market Cap | 20.13 kCr |
| Price/Earnings (Trailing) | 12.93 |
| Price/Sales (Trailing) | 4.15 |
| EV/EBITDA | 9.46 |
| Price/Free Cashflow | 11.36 |
| MarketCap/EBT | 10.86 |
| Enterprise Value | 20.28 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 4.85 kCr |
| Rev. Growth (Yr) | 8.3% |
| Earnings (TTM) | 1.56 kCr |
| Earnings Growth (Yr) | 14.3% |
Profitability | |
|---|---|
| Operating Margin | 38% |
| EBT Margin | 38% |
| Return on Equity | 17.97% |
| Return on Assets | 14.91% |
| Free Cashflow Yield | 8.8% |
Growth & Returns | |
|---|---|
| Price Change 1W | 9.4% |
| Price Change 1M | 8.1% |
| Price Change 6M | 32.9% |
| Price Change 1Y | 50.5% |
| 3Y Cumulative Return | 24.3% |
| 5Y Cumulative Return | 4% |
| 7Y Cumulative Return | 10.3% |
| 10Y Cumulative Return | 9.8% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -1.41 kCr |
| Cash Flow from Operations (TTM) | 1.7 kCr |
| Cash Flow from Financing (TTM) | -210.7 Cr |
| Cash & Equivalents | 103.5 Cr |
| Free Cash Flow (TTM) | 1.3 kCr |
| Free Cash Flow/Share (TTM) | 72.34 |
Balance Sheet | |
|---|---|
| Total Assets | 10.43 kCr |
| Total Liabilities | 1.78 kCr |
| Shareholder Equity | 8.65 kCr |
| Current Assets | 6.97 kCr |
| Current Liabilities | 1.7 kCr |
| Net PPE | 2.44 kCr |
| Inventory | 818 Cr |
| Goodwill | 59.7 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.02 |
| Debt/Equity | 0.03 |
| Interest Coverage | 50.46 |
| Interest/Cashflow Ops | 78.48 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 5 |
| Dividend Yield | 0.44% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | -1.9% |
Past Returns: Outperforming stock! In past three years, the stock has provided 24.3% return compared to 10.5% by NIFTY 50.
Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.
Profitability: Very strong Profitability. One year profit margin are 32%.
Balance Sheet: Strong Balance Sheet.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock price has a strong positive momentum. Stock is up 8.1% in last 30 days.
Insider Trading: Significant insider selling noticed recently.
Investor Care | |
|---|---|
| Dividend Yield | 0.44% |
| Dividend/Share (TTM) | 5 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 86.94 |
Financial Health | |
|---|---|
| Current Ratio | 4.1 |
| Debt/Equity | 0.03 |
Technical Indicators | |
|---|---|
| RSI (14d) | 80.93 |
| RSI (5d) | 100 |
| RSI (21d) | 63.58 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Natco Pharma's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Management of Natco Pharma provided a positive outlook during the Q2 FY26 earnings call held on November 14, 2025. Key highlights include:
Revenue Performance: The company reported consolidated revenue of Rs 1,463 crores for Q2 FY26, reflecting an increase from Rs 1,434.9 crores in Q2 FY25.
Profitability: EBITDA reached Rs 679.2 crores, with margins at 46.4%. The net profit for the period was Rs 517.9 crores.
Forward Guidance: For the second half of FY26, management expects a revenue run rate of Rs 750 to 800 crores per quarter and a profit after tax (PAT) of Rs 135 to 150 crores per quarter. This suggests an anticipated total PAT for H2 FY26 in the range of Rs 270 to 300 crores, in line with prior guidance.
R&D Investment: Management has been incurring substantial R&D expenses for bioequivalence studies related to Para-IV filings for generics, which is expected to boost future revenues.
Segment Developments: The domestic formulations segment is anticipated to stabilize, while international opportunities are set to grow, particularly with the expected launch of semaglutide in the first wave around March-April 2026.
Market Conditions: Management acknowledged increased competition for certain products, particularly Lenalidomide, and has not budgeted significant revenue from it for the upcoming quarters.
Strategic Moves: Natco plans to demerge its Crop Health Sciences segment, which has shown improved performance, positioning it for separate listing in 2026.
Future Product Pipeline: The company is targeting three to four additional Para-IV filings in H2 FY26 and expects to see substantial growth from FTF products through 2027 and beyond.
Overall, management exhibits confidence in the company's trajectory, emphasizing a focus on growth through strategic investments and an enhanced product pipeline.
1. Question from Rahul: "Does that mean it is for the purpose of Para-IV filings for generic drugs?"
Answer: "Yes, those expenses are indeed for Para-IV filings for generic drugs. We're also conducting clinical trials for first-time generics in India. The costs were higher due to one-time substantial expenses and expensive R&D purchases."
2. Question from Rahul: "What is the reason for the increase in provisions?"
Answer: "We had a good quarter, so we decided to make provisions for contingencies, including for patent litigation and business expenses. These provisions reflect routine business expenses rather than cash outflows."
3. Question from Rahul: "When can we expect to launch domestic semaglutide?"
Answer: "We're on target, having completed the review process. If we file in December, we hope to be among the first in the market, aiming for launch around March."
4. Question from Hrishikesh: "What is the way forward in 3Q and 4Q regarding revenue?"
Answer: "We've done well this quarter, but for Q3 and Q4, we're not expecting much change. Increased competition means we haven't budgeted much revenue from Lenalidomide because we're uncertain about market share."
5. Question from Hrishikesh: "What is the status on CTPR?"
Answer: "The CTPR combinations have performed well, growing to Rs.52 crores this quarter and nearing EBITDA positivity. We plan to demerge this segment in 2026 for better focus."
6. Question from Nitin Agarwal: "Any new Para-IV filings for F26?"
Answer: "We plan to file three to four new products soon. However, whether they will be sole FTFs remains uncertain until the filing process is complete."
7. Question from Nitin Agarwal: "How has the domestic business performed aside from Semaglutide?"
Answer: "Our domestic business remains stable, with a successful launch of Risdiplam. We expect solid performance next year, with Semaglutide being a major contributor."
8. Question from Kunal Randheria: "Any specific launches in the US for FY27 and FY28?"
Answer: "I cannot specify names at this time due to confidentiality, but we expect one or two launches in '26 and '27, while major launches are planned for '27 and '28."
9. Question from Kunal Randheria: "Why aren't we pursuing opportunities in other markets for Semaglutide?"
Answer: "We are focusing on the domestic market for now. The patent for South Africa will open later, and we primarily have a JV with Viatris for the US and other regulated markets."
10. Question from Rahul: "How will price reductions by US innovators impact our Semaglutide plans?"
Answer: "The opportunity is still vast. While there may be some disruption, capturing any share of the market will be beneficial given the overall size."
11. Question from MC Gupta: "Is there a takeover opportunity in the US?"
Answer: "We're always exploring investment options, with plenty of cash available post-Adcock acquisition. Any promising opportunity will be considered."
12. Question from Alok Chaudhary: "Do you expect significant cash from the Rs.3,900 crores fund for acquisitions soon?"
Answer: "Post-Adcock, we foresee cash settling around Rs.2,700-Rs.2,800 crores. The Semaglutide opportunity remains significant, even with competition."
This encapsulates the major questions and answers from the Q&A session of the earnings call. Let me know if you need any further assistance!
Analysis of Natco Pharma's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Pharmaceuticals | 95.6% | 618.9 Cr |
| Agro Chemicals | 4.4% | 28.4 Cr |
| Total | 647.3 Cr |
Understand Natco Pharma ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| V C NANNAPANENI | 15.66% |
| TIME CAP PHARMA LABS PRIVATE LIMITED | 9.59% |
| VENKATA SATYA SWATHI KANTAMANI | 8.9% |
| NATSOFT INFORMATION SYSTEMS PVT LTD | 8.81% |
| BELGRAVE INVESTMENT FUND | 2.31% |
| LIFE INSURANCE CORPORTION OF INDIA | 2.29% |
| Vistra ITCL India Limited A/c Neelima Nannapaneni Trust | 2.28% |
| DURGA DEVI NANNAPANENI | 1.98% |
| AKASH BHANSHALI | 1.01% |
| RAJEEV NANNAPANENI | 0.6% |
| Vistra ITCL India Limited A/c Durgadevi Family Trust | 0.33% |
| T ANILA | 0.32% |
| T ANANDA BABU | 0.23% |
| VIDYADHARI TUMMALA | 0.21% |
| SATYA VANI NANNAPANENI | 0.19% |
| NEELIMA SITA NANNAPANENI | 0.1% |
| SANJAY NANNAPANENI | 0.09% |
| NDL INFRATECH PRIVATE LIMITED | 0.05% |
| TUMMALA JANSI | 0.04% |
| KANTAMANI RATNA KUMAR | 0.03% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Natco Pharma against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.12 LCr | 58.94 kCr | -5.30% | +3.90% | 37.73 | 6.99 | - | - |
| LUPIN | Lupin | 1.05 LCr | 26.49 kCr | -1.80% | +19.60% | 22.56 | 3.96 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.01 LCr | 36.09 kCr | -7.80% | +10.80% | 18.12 | 2.8 | - | - |
| CIPLA | Cipla | 98.98 kCr | 29.37 kCr | -8.10% | -13.40% | 21.77 | 3.37 | - | - |
| AUROPHARMA | Aurobindo Pharma | 77.85 kCr | 33.73 kCr | +4.20% | +26.70% | 22.33 | 2.31 | - | - |
Comprehensive comparison against sector averages
NATCOPHARM metrics compared to Pharmaceuticals
| Category | NATCOPHARM | Pharmaceuticals |
|---|---|---|
| PE | 12.93 | 33.71 |
| PS | 4.15 | 4.65 |
| Growth | 5.2 % | 8 % |
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
NATCOPHARM vs Pharmaceuticals (2021 - 2026)